Third-generation cephalosporin resistance of community-onset Escherichia coli and Klebsiella pneumoniae bacteremia in a secondary hospital
2
조회
0
다운로드
4
인용
0
참고문헌
키워드
초록
Background/Aims: To enable appropriate antimicrobial treatment for community-onset infections in emergency departments (EDs), data are needed on the resistance profiles of Escherichia coli and Klebsiella pneumoniae, which are the main pathogens of community-onset bacteremia. Methods: Records were reviewed of 734 patients with E. coli and K. pneumoniae bacteremia who visited the Daegu Fatima Hospital ED, Daegu, Korea between 2003 and 2009. We investigated the demographic data, clinical findings, and antimicrobial susceptibility patterns of the organisms. Results: Of 1,208 cases of community-onset bacteremia, 62.8% were caused by E. coli or K. pneumoniae in an ED of a secondary care hospital. Five hundred and forty-eight cases of E. coli (75%) and 183 cases of K. pneumoniae (25%) were analyzed. Urinary tract infection (43.1%) was most common, followed by intra-abdominal infection (39%) and pneumonia (7.2%). Trimethoprim/sulfamethoxazole, fluoroquinolone, third-generation cephalosporin (3GC) and amikacin resistance rates among E. coli and K. pneumoniae were 22.8%, 19.6%, 6.2%, and 1.3%, respectively. In 2009, the rate of 3GC resistance (10.6%) was significantly higher, compared to the annual averages of 2003 to 2008 (6.1%; p = 0.03). Previous exposure to antibiotics was an independent risk factor for 3GC resistance in multivariate logistic regression analysis. Conclusions: The rate of 3GC resistance increased in community-onset infections, and previous exposure to antibiotics was an independent risk factor. Despite the increased 3GC resistance in community-onset infections, an amikacin combination therapy could provide an option for treatment of bacteremic patients with previous antibiotic exposure in an ED.
Abstract
Background/Aims: To enable appropriate antimicrobial treatment for community-onset infections in emergency departments (EDs), data are needed on the resistance profiles of Escherichia coli and Klebsiella pneumoniae, which are the main pathogens of community-onset bacteremia. Methods: Records were reviewed of 734 patients with E. coli and K. pneumoniae bacteremia who visited the Daegu Fatima Hospital ED, Daegu, Korea between 2003 and 2009. We investigated the demographic data, clinical findings, and antimicrobial susceptibility patterns of the organisms. Results: Of 1,208 cases of community-onset bacteremia, 62.8% were caused by E. coli or K. pneumoniae in an ED of a secondary care hospital. Five hundred and forty-eight cases of E. coli (75%) and 183 cases of K. pneumoniae (25%) were analyzed. Urinary tract infection (43.1%) was most common, followed by intra-abdominal infection (39%) and pneumonia (7.2%). Trimethoprim/sulfamethoxazole, fluoroquinolone, third-generation cephalosporin (3GC) and amikacin resistance rates among E. coli and K. pneumoniae were 22.8%, 19.6%, 6.2%, and 1.3%, respectively. In 2009, the rate of 3GC resistance (10.6%) was significantly higher, compared to the annual averages of 2003 to 2008 (6.1%; p = 0.03). Previous exposure to antibiotics was an independent risk factor for 3GC resistance in multivariate logistic regression analysis. Conclusions: The rate of 3GC resistance increased in community-onset infections, and previous exposure to antibiotics was an independent risk factor. Despite the increased 3GC resistance in community-onset infections, an amikacin combination therapy could provide an option for treatment of bacteremic patients with previous antibiotic exposure in an ED.
참고문헌 (24)
- Diekema DJ, "Survey of bloodstream infections due to gram-negative bacilli:frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, and Latin America for the SENTRY Antimicrobial Surveillance Program, 1997", Clin Infect Dis, 29, pp.595~607 (1999)
- Gupta K, "International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases", Clin Infect Dis, 52, pp.e103~e120 (2011)
- Solomkin JS, "Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America", Clin Infect Dis, 50, pp.133~164 (2010)
- Cheong HJ, "Bacteremia due to quinolone-resistant Escherichia coli in a teaching hospital in South Korea", Clin Infect Dis, 33, pp.48~53 (2001)
- Ena J, "Emergence of ciprof loxacin resistance in Escherichia coli isolates after widespread use of f luoroquinolones", Diagn Microbiol Infect Dis, 30, pp.103~107 (1998)
- 이혁민, "2005∼2006년 국내 12개 병원에서 분리된 주요 세균의 항균제 내성률", Annals of Clinical Microbiology, 10(1), pp.59~69 (2007), 대한임상미생물학회
- Hawser SP, "Incidence and antimicrobial susceptibility of Escherichia coli and Klebsiella pneumoniae with extended-spectrum beta-lactamases in communityand hospital-associated intra-abdominal infections in Europe: results of the 2008 Study for Monitoring Antimicrobial Resistance Trends (SMART)", Antimicrob Agents Chemother, 54, pp.3043~3046 (2010)
- Pitout JD, "Pop-ulation-based laboratory surveillance for AmpC betalactamase-producing Escherichia coli, Calgary", Emerg Infect Dis, 13, pp.443~448 (2007)
- Rodriguez-Bano J, "Communityonset bacteremia due to extended-spectrum betalactamase-producing Escherichia coli: risk factors and prognosis", Clin Infect Dis, 50, pp.40~48 (2010)
- Kang CI, "Risk factors and treatment outcomes of community-onset bacteraemia caused by extended-spectrum beta-lactamaseproducing Escherichia coli", Int J Antimicrob Agents, 36, pp.284~287 (2010)
- Charlson ME, "A new method of classifying prognostic comorbidity in longitudinal studies: development and validation", J Chronic Dis, 40, pp.373~383 (1987)
- Paterson DL, "International prospective study of Klebsiella pneumoniae bacteremia:implications of extended-spectrum beta-lactamase production in nosocomial Infections", Ann Intern Med, 140, pp.26~32 (2004)
- Courpon-Claudinon A, "Bacteraemia caused by third-generation cephalosporinresistant Escherichia coli in France: prevalence, molecular epidemiology and clinical features", Clin Microbiol Infect, 17, pp.557~565 (2011)
- Livermore DM, "BSAC Working Parties on Resistance Surveillance. Nonsusceptibility trends among Enterobacteriaceae from bacteraemias in the UK and Ireland, 2001-06", J Antimicrob Chemother, 62(Suppl 2), pp.ii41~ii54 (2008)
- Wang P, "Susceptibility of extended-spectrum-beta-lactamase-producing Enterobacteriaceae according to the new CLSI breakpoints", J Clin Microbiol, 49, pp.3127~3131 (2011)
- Song W, "CTX-M-14 and CTX-M-15enzymes are the dominant type of extended-spectrum beta-lactamase in clinical isolates of Escherichia coli from Korea", J Med Microbiol, 58(Pt 2), pp.261~266 (2009)
- Kang CI, "Risk factors for and clinical outcomes of bloodstream infections caused by extended-spectrum beta-lactamase-producing Klebsiella pneumoniae", Infect Control Hosp Epidemiol, 25, pp.860~867 (2004)
- Kim YK, "Bloodstream infections by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in children:epidemiology and clinical outcome", Antimicrob Agents Chemother, 46, pp.1481~1491 (2002)
- Menashe G, "Clinical significance and impact on mortality of extended-spectrum beta lactamase-producing Enterobacteriaceae isolates in nosocomial bacteremia", Scand J Infect Dis, 33, pp.188~193 (2001)
- Schwaber MJ, "Clinical and economic impact of bacteremia with extended-spectrum-beta-lactamaseproducing Enterobacteriaceae", Antimicrob Agents Chemother, 50, pp.1257~1262 (2006)
- Tumbarello M, "Bloodstream infections caused by extended-spectrum-betalactamase-producing Klebsiella pneumoniae: risk factors, molecular epidemiology, and clinical outcome", Antimicrob Agents Chemother, 50, pp.498~504 (2006)
- Paterson DL, "Extended-spectrum beta-lactamases:a clinical update", Clin Microbiol Rev, 18, pp.657~686 (2005)
- Kang CI, "Piperacillin-tazobactam as an initial empirical therapy of bacteremia caused by extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae", J Infect, 64, pp.533~534 (2012)
- Rodriguez-Bano J, "Extended-Spectrum Beta-Lactamases–Red Espanola de Investigacion en Patología Infecciosa", Grupo de Estudio de Infeccion Hospitalaria Group. β-Lactam, Clin Infect Dis, pp.2012, 54[DOI]